https://www.pharmaradar360.com/article/at-bio-tension-over-china-biotech-deal-regulation-looms-799efe1ec960b2cePharma Surgeen2026-06-26T16:03:46.000ZAt BIO, tension over China biotech deal regulation loomshttps://www.pharmaradar360.com/article/exg-7001-60b08321676c056fPharma Surgeen2026-06-26T16:00:00.000ZEXG-7001のオプション契約締結のお知らせhttps://www.pharmaradar360.com/article/ubs-raises-incyte-stock-price-target-to-113-on-biotech-recovery-fcf433cc718ef2fbPharma Surgeen2026-06-26T15:32:59.000ZUBS raises Incyte stock price target to $113 on biotech recoveryhttps://www.pharmaradar360.com/article/thermo-fisher-s-kane-says-ai-is-reshaping-how-cdmos-add-value-ff3d81f8099e425ePharma Surgeen2026-06-26T15:29:10.000ZThermo Fisher's Kane Says AI Is Reshaping How CDMOs Add Valuehttps://www.pharmaradar360.com/article/china-biotech-services-says-bgi-songhe-advances-rmb30-million-loan-to-pengbo-hai-9d6d59f536a82305Pharma Surgeen2026-06-26T15:25:48.000ZChina Biotech Services Says BGI Songhe Advances RMB30 Million Loan To Pengbo (Hainan)https://www.pharmaradar360.com/article/stanowisko-do-projektu-ustawy-o-zmianie-ustawy-o-refundacji-lekow-srodkow-spozyw-fe8e5deac4e53f12Pharma Surgeen2026-06-26T15:25:19.000ZStanowisko do projektu ustawy o zmianie ustawy o refundacji leków, środków spożywczych specjalnego przeznaczenia żywieniowego oraz wyrobów medycznych oraz niektórych innych ustawhttps://www.pharmaradar360.com/article/cold-chain-packaging-market-to-reach-93-1-billion-by-2033-amid-pharmaceutical-an-5bb80e6a19a0b259Pharma Surgeen2026-06-26T15:22:30.000ZCold Chain Packaging Market to Reach $93.1 Billion by 2033 Amid Pharmaceutical and E-commerce Pressureshttps://www.pharmaradar360.com/article/lupin-s-fda-nod-signals-shakeup-for-a-3-5b-prostate-cancer-drug-market-08fb7e8e8f7083ecPharma Surgeen2026-06-26T15:18:30.000ZLupin's FDA Nod Signals Shakeup for a $3.5B Prostate Cancer Drug Markethttps://www.pharmaradar360.com/article/exciting-clinical-trial-results-for-new-endometriosis-scan-6596c4417307b5c0Pharma Surgeen2026-06-26T15:15:38.000Z'Exciting' Clinical Trial Results For New Endometriosis Scanhttps://www.pharmaradar360.com/article/a-breakthrough-designated-depression-drug-is-86-through-its-phase-3-with-topline-d55ccf0549af2c24Pharma Surgeen2026-06-26T15:07:21.000ZA Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Yearhttps://www.pharmaradar360.com/article/definium-releases-lsd-for-depression-phase-3-results-and-colorado-activists-figh-9f86436c3c791addPharma Surgeen2026-06-26T15:02:59.000ZDefinium releases LSD for depression Phase 3 results and Colorado activists fight recent bill’s amendments to sharing psychedelicshttps://www.pharmaradar360.com/article/geodis-thermal-covers-mark-step-toward-sustainable-pharma-airfreight-packaging-a547fef357437168Pharma Surgeen2026-06-26T14:53:36.000ZGEODIS Thermal Covers Mark Step Toward Sustainable Pharma Airfreight Packaginghttps://www.pharmaradar360.com/article/fermenta-biotech-limited-ranked-7th-nationwide-in-india-s-great-mid-size-workpla-2ebc48c37d6d1d67Pharma Surgeen2026-06-26T14:43:15.000ZFermenta Biotech Limited Ranked 7th Nationwide in India’s Great Mid-size WorkplacesTM 2026https://www.pharmaradar360.com/article/weekly-buzz-ions-mrk-get-fda-approvals-achv-gets-crl-adct-cuts-jobs-tech-acquire-27ec8151deeb3f93Pharma Surgeen2026-06-26T14:33:00.000ZWeekly Buzz: IONS, MRK Get FDA Approvals; ACHV Gets CRL; ADCT Cuts Jobs; TECH Acquiredhttps://www.pharmaradar360.com/article/ukhsa-extends-red-heat-health-alerts-across-england-3ab1f8a5ec9bfc1dPharma Surgeen2026-06-26T14:17:52.000ZUKHSA extends red heat-health alerts across Englandhttps://www.pharmaradar360.com/article/register-medical-devices-to-place-on-the-market-931aab8eba5ff651Pharma Surgeen2026-06-26T14:03:03.000ZRegister medical devices to place on the markethttps://www.pharmaradar360.com/article/biogen-ends-apellis-research-programs-cuts-small-number-of-roles-after-5-6b-buyo-a14cdd3f8a43ea73Pharma Surgeen2026-06-26T13:56:36.000ZBiogen ends Apellis research programs, cuts ‘small number’ of roles after $5.6B buyouthttps://www.pharmaradar360.com/article/bio-2026-making-biotech-ipos-great-again-and-the-forgotten-pharma-antitrust-revi-e593f42e9daba114Pharma Surgeen2026-06-26T13:51:22.000ZBIO 2026: Making biotech IPOs great again and the forgotten pharma antitrust reviewhttps://www.pharmaradar360.com/article/price-to-book-forward-of-sunhawk-vision-biotech-inc-tpex-7759-3d9ee68754f503ccPharma Surgeen2026-06-26T13:44:14.000ZPrice to book forward of Sunhawk Vision Biotech, Inc. – TPEX:7759https://www.pharmaradar360.com/article/embryo-editing-advances-reignite-ethical-debates-09ff37118eb1b533Pharma Surgeen2026-06-26T13:43:09.000ZEmbryo editing advances reignite ethical debateshttps://www.pharmaradar360.com/article/pharmaceutical-market-europe-june-2026-d84b311e3cdc4fe0Pharma Surgeen2026-06-26T13:42:16.000ZPharmaceutical Market Europe – June 2026https://www.pharmaradar360.com/article/a-breakthrough-designated-depression-drug-is-86-through-its-phase-3-with-topline-46655b8d8f56d95bPharma Surgeen2026-06-26T13:30:00.000ZA Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Yearhttps://www.pharmaradar360.com/article/has-ocugen-s-recent-convertible-notes-offering-stabilized-its-financial-future-24b60403ee69b13dPharma Surgeen2026-06-26T13:29:29.000ZHas Ocugen's Recent Convertible Notes Offering Stabilized Its Financial Futurehttps://www.pharmaradar360.com/article/the-deal-before-the-deal-3b0eab5c7eeeaf77Pharma Surgeen2026-06-26T13:20:55.000ZThe deal before the dealhttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-rtw-biotech-opportunities-ltd-usd-fwb-0bm-eef44425562356c9Pharma Surgeen2026-06-26T13:14:48.000ZEnterprise value to EBITDA forward of RTW Biotech Opportunities Ltd USD – FWB:0BMhttps://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-grand-pharmaceutical-group-limited-hkex-5-9e7a26a761bff9c6Pharma Surgeen2026-06-26T13:10:38.000ZEnterprise value to revenue forward of Grand Pharmaceutical Group Limited – HKEX:512https://www.pharmaradar360.com/article/capricor-to-present-positive-five-year-hope-2-ole-data-and-hope-3-phase-3-result-9eaf760c148df482Pharma Surgeen2026-06-26T13:07:58.000ZCapricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conferencehttps://www.pharmaradar360.com/article/how-china-turned-us-trade-compliance-into-a-supply-chain-risk-91493386362eb16aPharma Surgeen2026-06-26T13:07:30.000ZHow China Turned US Trade Compliance Into a Supply Chain Riskhttps://www.pharmaradar360.com/article/it-s-time-to-act-eu-biotech-to-undergo-major-changes-4606aca6feae95acPharma Surgeen2026-06-26T13:02:05.000Z“It’s time to Act”: EU biotech to undergo major changeshttps://www.pharmaradar360.com/article/moderna-enters-in-vivo-car-t-granting-autoimmune-asset-007-license-to-kill-patho-8c14142fe7c43039Pharma Surgeen2026-06-26T13:00:00.000ZModerna enters in vivo CAR-T, granting autoimmune asset ‘007’ license to kill pathogenic cellshttps://www.pharmaradar360.com/article/don-t-make-ai-smarter-make-it-traceable-3dda76f53f2eefc0Pharma Surgeen2026-06-26T12:58:43.000ZDon’t Make AI Smarter. Make It Traceable.https://www.pharmaradar360.com/article/remifentanil-hydrochloride-for-injection-out-of-specification-assay-impurity-9908a70cfc71811bPharma Surgeen2026-06-26T12:00:00.000ZRemifentanil hydrochloride for injection; Out of specification (Assay & Impurity)https://www.pharmaradar360.com/article/turbo-69-54506e9db44a827fPharma Surgeen2026-06-26T11:55:42.000ZTURBO 69 (ΣΤΑΓΟΝΕΣ) / (ΣΙΛΔΕΝΑΦΙΛΗ)https://www.pharmaradar360.com/article/vericel-corp-nasdaq-vcel-a-classic-affordable-growth-stock-in-biotech-362d3e9dd2d3a02bPharma Surgeen2026-06-26T11:50:35.000ZVericel Corp (NASDAQ:VCEL): A Classic Affordable Growth Stock in Biotechhttps://www.pharmaradar360.com/article/group-files-brief-urging-fda-s-reinstatement-of-abortion-pill-restriction-2fb78cd02a61d657Pharma Surgeen2026-06-26T11:50:00.000ZGroup files brief urging FDA's reinstatement of abortion pill restrictionhttps://www.pharmaradar360.com/article/241105viy-10-2027-ref-pga30f0126-rt-med-75cm-usp-3-0-ep-metric-1-2-26-6912ac734b17d5fcPharma Surgeen2026-06-26T11:43:56.000ZΟΡΘΗ-Ανάκληση της παρτίδας 241105VIY, ημ λήξης: 10/2027, (REF: PGA30F0126), του ιατροτεχνολογικού προϊόντος ΧΕΙΡΟΥΡΓΙΚΑ ΡΑΜΜΑΤΑ RT MED Πολύκλωνο Συνθετικό Απορροφήσιμο Πλεκτό Ράμμα – Βιολετί, 75CM, USP 3/0, EP METRIC 1/2 κύκλου, στρογγυλή βελόνη 26 χιλhttps://www.pharmaradar360.com/article/why-is-intellia-therapeutics-ntla-a-battleground-stock-with-38-short-interest-ac440ef295d82fe1Pharma Surgeen2026-06-26T11:40:27.000ZWhy is Intellia Therapeutics (NTLA) a Battleground Stock with 38% Short Interesthttps://www.pharmaradar360.com/article/imcd-opens-us-dietary-supplements-technical-hub-to-accelerate-innovation-ca77610be432afa4Pharma Surgeen2026-06-26T11:35:25.000ZIMCD opens US dietary supplements technical hub to accelerate innovationhttps://www.pharmaradar360.com/article/240592-perfume-mall-women-s-eau-de-perfume-1aa1c0d0246f391aPharma Surgeen2026-06-26T11:34:43.000ZΑνάκληση της παρτίδας 240592, του καλλυντικού προϊόντος Perfume Mall WOMEN’S EAU DE PERFUMEhttps://www.pharmaradar360.com/article/vivani-medical-announces-appointment-of-august-j-moretti-to-board-of-directors-a-2d214fdf66cad5b4Pharma Surgeen2026-06-26T11:30:00.000ZVivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean Bakerhttps://www.pharmaradar360.com/article/q-a-why-pharma-deal-volume-is-down-but-value-is-up-0abfb6604ec9d586Pharma Surgeen2026-06-26T11:29:06.000ZQ&A: Why Pharma Deal Volume Is Down but Value Is Uphttps://www.pharmaradar360.com/article/21393a07c-tesori-d-oriente-fior-di-loto-aromatic-perfume-100ml-bb602a3a10c8776cPharma Surgeen2026-06-26T11:26:48.000ZΑνάκληση της παρτίδας 21393A07C, του καλλυντικού προϊόντος Tesori d’ Oriente Fior di Loto Aromatic Perfume 100mlhttps://www.pharmaradar360.com/article/manushield-cleaner-d4dab93d8cc47949Pharma Surgeen2026-06-26T11:22:29.000ZΑνάκληση παρτίδας του προϊόντος MANUSHIELD CLEANERhttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-purple-biotech-ltd-nasdaq-ppbt-54c36a7050cbbfa0Pharma Surgeen2026-06-26T11:22:20.000ZEnterprise value to EBITDA forward of Purple Biotech Ltd. – NASDAQ:PPBThttps://www.pharmaradar360.com/article/now-zinc-gluconate-50mg-250-tabs-93c4f17b9d93a07bPharma Surgeen2026-06-26T11:18:26.000ZΑπαγόρευση διάθεσης και διακίνησης του συμπληρώματος διατροφής NOW ZINC GLUCONATE 50MG, 250 TABShttps://www.pharmaradar360.com/article/lilly-s-jaypirca-pirtobrutinib-recommended-by-chmp-for-approval-in-the-european-ed46d54504400b6aPharma Surgeen2026-06-26T11:16:00.000ZLilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapyhttps://www.pharmaradar360.com/article/axsome-starts-phase-3-trial-of-solriamfetol-for-adhd-in-adolescents-aiming-to-im-b350e465b798b6dcPharma Surgeen2026-06-26T11:15:21.000ZAxsome starts Phase 3 trial of solriamfetol for ADHD in adolescents, aiming to improve treatment options.https://www.pharmaradar360.com/article/hiro-lab-tongkat-ali-400mg-hiro-lab-turkesterone-600mg-1c8da9c4681bb79cPharma Surgeen2026-06-26T11:11:38.000ZΑπαγόρευση διάθεσης και διακίνησης των συμπληρωμάτων διατροφής Hiro.Lab Tongkat Ali 400MG, Hiro.Lab Turkesterone 600mghttps://www.pharmaradar360.com/article/compound-pharmacies-are-outrunning-regulations-experts-want-tougher-oversight-a4d199120cadaea9Pharma Surgeen2026-06-26T11:08:31.000ZCompound pharmacies are outrunning regulations. Experts want tougher oversight.https://www.pharmaradar360.com/article/key-takeaways-from-a-chronicle-examination-of-empower-pharmacy-3f7bc426d7b1091cPharma Surgeen2026-06-26T11:08:31.000ZKey takeaways from a Chronicle examination of Empower Pharmacyhttps://www.pharmaradar360.com/article/here-s-how-we-examined-houston-based-empower-pharmacy-s-expansion-2c4a74ba264d1b69Pharma Surgeen2026-06-26T11:08:31.000ZHere's how we examined Houston-based Empower Pharmacy's expansionhttps://www.pharmaradar360.com/article/axsome-therapeutics-initiates-focus-3-phase-3-trial-of-solriamfetol-in-adolescen-7e4e528b4f776335Pharma Surgeen2026-06-26T11:05:29.000ZAxsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)https://www.pharmaradar360.com/article/omakase-world-market-is-the-bay-area-s-most-surprising-new-food-hall-31b68bc365e513a5Pharma Surgeen2026-06-26T11:03:07.000ZOmakase World Market is the Bay Area's most surprising new food hallhttps://www.pharmaradar360.com/article/fda-to-discuss-easing-restrictions-on-peptides-despite-safety-concerns-ba8fa9e1bcd94824Pharma Surgeen2026-06-26T11:02:00.000ZFDA to discuss easing restrictions on peptides despite safety concernshttps://www.pharmaradar360.com/article/fda-weighs-legalizing-gray-market-peptides-amid-escalating-safety-concerns-05eb29b1ca1d6519Pharma Surgeen2026-06-26T11:00:16.000ZFDA Weighs Legalizing Gray-Market Peptides Amid Escalating Safety Concernshttps://www.pharmaradar360.com/article/axsome-starts-468-patient-adhd-trial-for-teens-4d97a5f680596e79Pharma Surgeen2026-06-26T11:00:00.000ZAxsome starts 468-patient ADHD trial for teenshttps://www.pharmaradar360.com/article/aethlon-medical-tracks-ebola-outbreak-readies-hemopurifier-talks-9f3bb3559a64882bPharma Surgeen2026-06-26T11:00:00.000ZAethlon Medical tracks Ebola outbreak, readies Hemopurifier talkshttps://www.pharmaradar360.com/article/from-vaccines-to-therapeutics-how-biotech-is-addressing-the-ebola-outbreak-a75589f8f3267be3Pharma Surgeen2026-06-26T11:00:00.000ZFrom Vaccines to Therapeutics; How Biotech Is Addressing the Ebola Outbreakhttps://www.pharmaradar360.com/article/mediterrania-portfolio-company-laprophan-acquires-rivopharm-7c4b9231a6f0ce65Pharma Surgeen2026-06-26T10:40:17.000ZMediterrania portfolio company Laprophan acquires Rivopharmhttps://www.pharmaradar360.com/article/tryngolza-charts-blockbuster-course-after-fda-s-hypertriglyceridemia-approval-2d918ec660c14cfePharma Surgeen2026-06-26T10:33:39.000ZTryngolza charts blockbuster course after FDA’s hypertriglyceridemia approvalhttps://www.pharmaradar360.com/article/quarterly-epidemiological-commentary-mandatory-mrsa-mssa-and-gram-negative-bacte-21e80aa813c48412Pharma Surgeen2026-06-26T10:32:27.000ZQuarterly Epidemiological Commentary: mandatory MRSA, MSSA and Gram-negative bacteraemia and Clostridioides difficile infection, data up to January to March 2026https://www.pharmaradar360.com/article/mexiletine-pr-564e51f22fbdac57Pharma Surgeen2026-06-26T10:21:39.000ZMexiletine PRhttps://www.pharmaradar360.com/article/hepatitis-b-antenatal-screening-and-selective-neonatal-immunisation-pathway-d8b93786f729959cPharma Surgeen2026-06-26T10:11:56.000ZHepatitis B: antenatal screening and selective neonatal immunisation pathwayhttps://www.pharmaradar360.com/article/decision-orphan-registered-medicinal-products-20a088b198fbcb50Pharma Surgeen2026-06-26T10:06:50.000ZDecision: Orphan registered medicinal productshttps://www.pharmaradar360.com/article/uk-malaria-expert-advisory-group-ukmeag-6b3d8243950c8703Pharma Surgeen2026-06-26T10:02:56.000ZUK Malaria Expert Advisory Group (UKMEAG)https://www.pharmaradar360.com/article/kazde-1-euro-zainwestowane-w-nowe-leki-przynosi-europie-5-67-euro-zwrotu-a686d6d0c71a0289Pharma Surgeen2026-06-26T09:49:10.000ZKażde 1 euro zainwestowane w nowe leki przynosi Europie 5,67 euro zwrotu.https://www.pharmaradar360.com/article/bio-2026-former-fda-staff-question-agency-s-radical-transparency-approach-15f344ca3097def3Pharma Surgeen2026-06-26T09:47:01.000ZBIO 2026: Former FDA staff question agency’s “radical transparency” approachhttps://www.pharmaradar360.com/article/san-diego-biopharma-begins-first-in-human-dosing-of-obesity-drug-as-phase-3-cata-892ffe88dada61d6Pharma Surgeen2026-06-26T09:45:15.000ZSan Diego Biopharma Begins First-in-Human Dosing of Obesity Drug as Phase 3 Catalysts Approachhttps://www.pharmaradar360.com/article/intrathecal-antibody-test-request-form-ad4dcac995d99f1dPharma Surgeen2026-06-26T09:44:26.000ZIntrathecal antibody test request formhttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-consun-pharmaceutical-group-ltd-hkex-1681-10dd56e132a422dbPharma Surgeen2026-06-26T09:44:13.000ZEnterprise value to EBIT forward of Consun Pharmaceutical Group Ltd. – HKEX:1681https://www.pharmaradar360.com/article/polyomavirus-jc-investigation-request-form-e13-5572d7f1731b0921Pharma Surgeen2026-06-26T09:40:57.000ZPolyomavirus JC investigation request form E13https://www.pharmaradar360.com/article/us-biotech-index-hits-record-high-danske-bank-cites-several-drivers-4077e21bef5cc833Pharma Surgeen2026-06-26T09:40:00.000ZUS biotech index hits record high, Danske Bank cites several drivershttps://www.pharmaradar360.com/article/price-to-book-forward-of-dizal-jiangsu-pharmaceutical-co-ltd-class-a-sse-688192-45cb49674c0d409fPharma Surgeen2026-06-26T09:37:52.000ZPrice to book forward of Dizal (Jiangsu) Pharmaceutical Co. Ltd. Class A – SSE:688192https://www.pharmaradar360.com/article/parvovirus-b19-referral-form-8dc7a59f7518c10aPharma Surgeen2026-06-26T09:37:08.000ZParvovirus B19 referral formhttps://www.pharmaradar360.com/article/varicella-zoster-virus-referral-form-87218879c2490674Pharma Surgeen2026-06-26T09:32:34.000ZVaricella zoster virus referral formhttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-shandong-xinhua-pharmaceutical-company-limit-5e0bf2c3a3a6cab4Pharma Surgeen2026-06-26T09:31:13.000ZEnterprise value to EBIT forward of Shandong Xinhua Pharmaceutical Company Limited Class H – LSX:A0M4YVhttps://www.pharmaradar360.com/article/hhv-6-and-hhv-7-referral-form-a9e04d646937cbb7Pharma Surgeen2026-06-26T09:26:29.000ZHHV-6 and HHV-7 referral formhttps://www.pharmaradar360.com/article/cnx-and-legacy-set-july-us-relaunch-for-ethyol-ebe5303f1be89f14Pharma Surgeen2026-06-26T09:21:54.000ZCNX and Legacy set July US relaunch for Ethyolhttps://www.pharmaradar360.com/article/otsuka-posts-positive-phase-iiib-data-for-novel-adhd-therapy-822dbafb438e1266Pharma Surgeen2026-06-26T09:11:51.000ZOtsuka posts positive Phase IIIb data for novel ADHD therapyhttps://www.pharmaradar360.com/article/how-ibio-aims-to-stand-out-in-obesity-by-targeting-both-sides-of-the-equation-fo-0be528ca5f6669fbPharma Surgeen2026-06-26T09:00:14.000ZHow iBio aims to stand out in obesity by targeting ‘both sides of the equation’ for antibody discoveryhttps://www.pharmaradar360.com/article/disponibilite-amelioree-du-zypadhera-poudre-et-solvant-pour-suspension-injectabl-b3a54536fec61316Pharma Surgeen2026-06-26T08:53:52.000ZDisponibilité améliorée du Zypadhera (poudre et solvant pour suspension injectable à libération prolongée) : assouplissement et recommandations adaptées pour les médecins (spécialistes), les pharmaciens (hospitaliers) et les patientshttps://www.pharmaradar360.com/article/debt-to-equity-ratio-of-gin-hwa-biotech-inc-tpex-7806-01f378f4e1b93d46Pharma Surgeen2026-06-26T08:53:50.000ZDebt to equity ratio of Gin Hwa Biotech, Inc. – TPEX:7806https://www.pharmaradar360.com/article/pharmaceutical-technology-fb92345e3e5c13daPharma Surgeen2026-06-26T08:53:38.000ZPharmaceutical Technologyhttps://www.pharmaradar360.com/article/explosion-and-fire-at-pharmaceutical-facility-in-new-york-state-0516ee6382f69c90Pharma Surgeen2026-06-26T08:48:16.000ZExplosion and fire at pharmaceutical facility in New York Statehttps://www.pharmaradar360.com/article/long-term-debt-to-total-assets-ratio-of-gin-hwa-biotech-inc-tpex-7806-c7ca9b20a6acfc5fPharma Surgeen2026-06-26T08:44:04.000ZLong term debt to total assets ratio of Gin Hwa Biotech, Inc. – TPEX:7806https://www.pharmaradar360.com/article/enterprise-value-of-gin-hwa-biotech-inc-tpex-7806-a8afe7c5336ff10fPharma Surgeen2026-06-26T08:41:49.000ZEnterprise value of Gin Hwa Biotech, Inc. – TPEX:7806https://www.pharmaradar360.com/article/debt-to-assets-ratio-of-gin-hwa-biotech-inc-tpex-7806-967f7174ee40d795Pharma Surgeen2026-06-26T08:40:53.000ZDebt to assets ratio of Gin Hwa Biotech, Inc. – TPEX:7806https://www.pharmaradar360.com/article/krystal-biotech-krys-rallies-on-pipeline-optimism-is-the-stock-already-pricey-fee4ba808a83171fPharma Surgeen2026-06-26T08:39:03.000ZKrystal Biotech (KRYS) Rallies On Pipeline Optimism, Is The Stock Already Pricey?https://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-gin-hwa-biotech-inc-tpex-7806-e536e0169386cdbfPharma Surgeen2026-06-26T08:37:48.000ZEnterprise value to EBIT forward of Gin Hwa Biotech, Inc. – TPEX:7806https://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-gin-hwa-biotech-inc-tpex-7806-5282c66628bef04aPharma Surgeen2026-06-26T08:37:06.000ZEnterprise value to revenue forward of Gin Hwa Biotech, Inc. – TPEX:7806https://www.pharmaradar360.com/article/price-to-book-forward-of-pharmagreen-biotech-inc-otc-phbi-877eb5b0e73534adPharma Surgeen2026-06-26T08:37:02.000ZPrice to book forward of Pharmagreen Biotech Inc. – OTC:PHBIhttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-ratio-of-gin-hwa-biotech-inc-tpex-7806-5cf1854633d84a95Pharma Surgeen2026-06-26T08:36:52.000ZEnterprise value to EBITDA ratio of Gin Hwa Biotech, Inc. – TPEX:7806https://www.pharmaradar360.com/article/operating-margin-of-gin-hwa-biotech-inc-tpex-7806-cfd5502829f86eebPharma Surgeen2026-06-26T08:36:17.000ZOperating margin % of Gin Hwa Biotech, Inc. – TPEX:7806https://www.pharmaradar360.com/article/net-margin-of-gin-hwa-biotech-inc-tpex-7806-64015955cdc56150Pharma Surgeen2026-06-26T08:35:33.000ZNet margin % of Gin Hwa Biotech, Inc. – TPEX:7806https://www.pharmaradar360.com/article/uk-biotech-thalia-therapeutics-raises-3-1-million-and-acquires-sanmirna-therapeu-c97cd65a592b2ee4Pharma Surgeen2026-06-26T08:34:20.000ZUK BioTech Thalia Therapeutics raises €3.1 million and acquires Sanmirna Therapeuticshttps://www.pharmaradar360.com/article/internal-eu-document-biotech-act-has-only-limited-impact-e7327a15d15f6f0fPharma Surgeen2026-06-26T08:31:47.000ZInternal EU document: Biotech Act has only limited impacthttps://www.pharmaradar360.com/article/new-aspe-report-finds-u-s-revenue-fuels-disproportionate-share-of-pharmaceutical-2377f20dbad85fc4Pharma Surgeen2026-06-26T08:31:00.000ZNew ASPE Report Finds U.S. Revenue Fuels Disproportionate Share of Pharmaceutical R&D Incentiveshttps://www.pharmaradar360.com/article/clostridioides-difficile-ribotyping-network-cdrn-report-cd445f04a8fc7f7fPharma Surgeen2026-06-26T08:30:00.000ZClostridioides difficile ribotyping network (CDRN) reporthttps://www.pharmaradar360.com/article/1-2026-811dc4dddb802ca1Pharma Surgeen2026-06-26T08:25:50.000ZΤιμολόγηση Νέων Φαρμακευτικών Προϊόντων_Νέα 1ου Τριμήνου 2026_Ανατιμολόγηση προϊόντων αναφοράς λόγω λήξης της προστασίας δεδομένων τους_Εξέταση αιτημάτων αναπροσαρμογής τιμής μη αποζημιούμενων σκευασμάτωνhttps://www.pharmaradar360.com/article/dhsc-business-appointment-rules-advice-3b5125a476d37863Pharma Surgeen2026-06-26T08:23:33.000ZDHSC: business appointment rules advicehttps://www.pharmaradar360.com/article/dhsc-business-appointment-rules-advice-january-to-march-2026-9c825b6c03b30e94Pharma Surgeen2026-06-26T08:23:31.000ZDHSC: business appointment rules advice, January to March 2026https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-28-june-2026-d61cebbdb2add2dePharma Surgeen2026-06-26T08:13:06.000ZWeekly all-cause mortality surveillance: week ending 28 June 2026https://www.pharmaradar360.com/article/is-viking-therapeutics-stock-a-no-brainer-buy-below-35-a528898970a236d0Pharma Surgeen2026-06-26T08:12:21.000ZIs Viking Therapeutics Stock a No-Brainer Buy Below $35?https://www.pharmaradar360.com/article/women-should-be-valued-and-protected-in-pregnancy-heartbeat-weighs-in-on-abortio-410c1628f6a12456Pharma Surgeen2026-06-26T08:01:54.000Z“Women should be valued and protected in pregnancy” – Heartbeat weighs in on abortion pill casehttps://www.pharmaradar360.com/article/lilly-launches-the-memory-radio-station-across-europe-inviting-the-public-to-vis-a0c91c981e0a2b2ePharma Surgeen2026-06-26T08:00:00.000ZLilly launches “The Memory Radio Station” across Europe, inviting the public to visually reconstruct fading memories through GenAIhttps://www.pharmaradar360.com/article/expired-gear-missing-records-2-mumbai-thane-blood-centres-shut-over-safety-lapse-4c338748db5d7bd7Pharma Surgeen2026-06-26T07:41:03.000ZExpired gear, missing records: 2 Mumbai, Thane blood centres shut over safety lapseshttps://www.pharmaradar360.com/article/proqr-validates-rna-editing-platform-and-raises-59-2m-fb73a6cbf3661ba9Pharma Surgeen2026-06-26T07:37:20.000ZProQR validates RNA editing platform and raises $59.2mhttps://www.pharmaradar360.com/article/assenagon-asset-management-s-a-decreases-stock-holdings-in-teva-pharmaceutical-i-340ad7b850fadc3aPharma Surgeen2026-06-26T07:17:58.000ZAssenagon Asset Management S.A. Decreases Stock Holdings in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/what-does-briacell-s-latest-offering-mean-for-shareholders-0945e6fa4f984948Pharma Surgeen2026-06-26T06:55:58.000ZWhat Does BriaCell's Latest Offering Mean for Shareholdershttps://www.pharmaradar360.com/article/gcp-breakdown-at-king-s-college-hospital-just-clouded-the-most-promising-parkins-5284224154e6aa79Pharma Surgeen2026-06-26T06:53:06.000ZGCP Breakdown at King’s College Hospital Just Clouded the Most Promising Parkinson’s Trial in Yearshttps://www.pharmaradar360.com/article/unapproved-retatrutide-use-challenges-clinicians-a54228fb90667cfdPharma Surgeen2026-06-26T06:42:33.000ZUnapproved Retatrutide Use Challenges Clinicianshttps://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-teva-pharmaceutical-industries-limited-sp-18729f331f01cd3dPharma Surgeen2026-06-26T06:35:22.000ZEnterprise value to revenue forward of Teva Pharmaceutical Industries Limited Sponsored ADR – FWB:TEVhttps://www.pharmaradar360.com/article/helus-shares-experience-studying-adjunctive-psychedelic-for-major-depressive-dis-4b3d93d40f3cc793Pharma Surgeen2026-06-26T06:31:40.000ZHelus Shares Experience Studying Adjunctive Psychedelic For Major Depressive Disorderhttps://www.pharmaradar360.com/article/rtw-biotech-invests-1-4-million-in-lycia-series-d-financing-3354a90a154b3c54Pharma Surgeen2026-06-26T06:30:00.000ZRTW Biotech Invests $1.4 Million In Lycia Series D Financinghttps://www.pharmaradar360.com/article/3-clinical-stage-biotech-stocks-worth-watching-in-parkinson-s-research-ddf5ae08cf0d24b4Pharma Surgeen2026-06-26T06:22:08.000Z3 Clinical-Stage Biotech Stocks Worth Watching In Parkinson's Researchhttps://www.pharmaradar360.com/article/korea-s-chip-fund-makes-first-biotech-bet-backing-ligachem-with-323-million-719fc6787bbc7329Pharma Surgeen2026-06-26T06:19:52.000ZKorea's chip fund makes first biotech bet, backing LigaChem with $323 millionhttps://www.pharmaradar360.com/article/korea-s-chip-fund-makes-first-biotech-bet-backing-ligachem-with-323-million-202b0cd2cf33f5afPharma Surgeen2026-06-26T05:50:13.000ZKorea's chip fund makes first biotech bet, backing LigaChem with $323 millionhttps://www.pharmaradar360.com/article/first-aid-biotech-act-deal-by-christmas-95157e9e88af4606Pharma Surgeen2026-06-26T05:48:01.000ZFIRST AID: Biotech Act deal by Christmas?https://www.pharmaradar360.com/article/lupin-gets-tentative-us-fda-approval-for-generic-prostate-cancer-drug-9fc4898b6ced2be7Pharma Surgeen2026-06-26T05:29:01.000ZLupin gets tentative US FDA approval for generic prostate cancer drughttps://www.pharmaradar360.com/article/from-data-to-decisions-how-ipsen-turns-medical-data-into-action-for-patients-ea0233d867d2b2abPharma Surgeen2026-06-26T05:01:55.000ZFrom data to decisions: how Ipsen turns medical data into action for patientshttps://www.pharmaradar360.com/article/why-is-sanofi-s-tolebrutinib-facing-a-regulatory-split-941a9c08b59ee378Pharma Surgeen2026-06-26T04:38:53.000ZWhy is Sanofi's Tolebrutinib Facing a Regulatory Splithttps://www.pharmaradar360.com/article/what-do-moonlake-s-latest-week-40-hs-results-really-mean-for-investors-9f702ce2a4a5c8ffPharma Surgeen2026-06-26T03:14:47.000ZWhat Do MoonLake's Latest Week 40 HS Results Really Mean for Investorshttps://www.pharmaradar360.com/article/how-glp-1-demand-is-reshaping-pharma-manufacturing-strategy-449d3c541f79107aPharma Surgeen2026-06-26T01:58:08.000ZHow GLP-1 Demand Is Reshaping Pharma Manufacturing Strategyhttps://www.pharmaradar360.com/article/what-does-breakthrough-therapy-designation-mean-for-relay-therapeutics-0552e377f4ba3054Pharma Surgeen2026-06-26T01:37:17.000ZWhat Does Breakthrough Therapy Designation Mean for Relay Therapeuticshttps://www.pharmaradar360.com/article/drug-maker-sues-to-halt-implementation-of-arkansas-new-pharmaceutical-distributi-3bc547afe7c747d7Pharma Surgeen2026-06-26T01:30:00.000ZDrug maker sues to halt implementation of Arkansas' new pharmaceutical distribution lawhttps://www.pharmaradar360.com/article/recce-pharmaceuticals-rce-investor-presentation-summary-0037e81161ff9200Pharma Surgeen2026-06-26T01:28:31.000ZRecce Pharmaceuticals (RCE) Investor presentation Summaryhttps://www.pharmaradar360.com/article/recce-raises-a-4m-as-it-advances-anti-infective-trials-and-commercial-licensing-05a6e7bac0e1db4ePharma Surgeen2026-06-26T01:12:16.000ZRecce raises A$4M as it advances anti-infective trials and commercial licensing plans; another $4M to come in SPPhttps://www.pharmaradar360.com/article/hong-kong-biotech-delegation-makes-strong-us-showing-at-bio-2026-50eeed6bead0c6d0Pharma Surgeen2026-06-26T01:10:08.000ZHong Kong biotech delegation makes strong US showing at BIO 2026https://www.pharmaradar360.com/article/dailypharmkorea-239d9f58bc2463c6Pharma Surgeen2026-06-26T00:50:24.000Z데일리팜코리아, 데일리팜 영문뉴스, dailypharmkoreahttps://www.pharmaradar360.com/article/us-fda-declines-to-approve-achieve-life-sciences-smoking-cessation-drug-7f39ea1a8193483fPharma Surgeen2026-06-26T00:41:20.000ZUS FDA declines to approve Achieve Life Sciences' smoking-cessation drughttps://www.pharmaradar360.com/article/gsk-filed-form-6-k-cba2126807971e0bPharma Surgeen2026-06-26T00:00:00.000ZGSK filed Form 6-Khttps://www.pharmaradar360.com/article/santen-obtains-marketing-approval-in-the-philippines-for-stn1012700-ryjusea-0-25-c50cd231bb348a46Pharma Surgeen2026-06-26T00:00:00.000ZSanten Obtains Marketing Approval in the Philippines for STN1012700 (Ryjusea 0.25mg/mL Ophthalmic Solution), an Ophthalmic Solution to Slow the Progression of Myopia — First Approval in Santen’s Asia Business Regionhttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-40cf7cf002d36d75Pharma Surgeen2026-06-26T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-44c0532613516e29Pharma Surgeen2026-06-26T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b91463-crore-consolidated-revenue-and-e2-82-b9517-9-crore-of-dbe485666a40899fPharma Surgeen2026-06-26T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-4230d64e81acd0ecPharma Surgeen2026-06-26T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-37e0607ce5410c12Pharma Surgeen2026-06-26T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-88e664c7644b0c4cPharma Surgeen2026-06-26T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-d9c52d839cb9bf84Pharma Surgeen2026-06-26T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-3e71d955558b752fPharma Surgeen2026-06-26T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-announces-launch-of-its-everolimus-tablets-1-mg-generic-of-zortress-9534a207a0ad4f40Pharma Surgeen2026-06-26T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-5e515ca7a216fb62Pharma Surgeen2026-06-26T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-0de1dfd7d06b05f0Pharma Surgeen2026-06-26T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-1e658f374adfa84bPharma Surgeen2026-06-26T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/adcock-ingram-completes-delisting-from-jse-natco-pharma-acquires-35-75-stake-001eb51041da80d6Pharma Surgeen2026-06-26T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/home-page-bf13e4cf8344a7d3Pharma Surgeen2026-06-26T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-pro-1e4392a0904f6fb2Pharma Surgeen2026-06-26T00:00:00.000ZAgency Information Collection Activities: Proposed Collection; Comment Request Proposed Project: Request To Publish the 30-Day Notices in the Federal Register To Solicit Public Comment on Information Collection for the Continued Approval and Updates for the Protection and Advocacy for Individuals Wihttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-office-of-management-and-d412273cbac0868fPharma Surgeen2026-06-26T00:00:00.000ZAgency Information Collection Activities: Submission for Office of Management and Budget Review (OMB); Comment Requesthttps://www.pharmaradar360.com/article/proposed-information-collection-activity-tanf-contingency-fund-application-8e6717d5e53dca83Pharma Surgeen2026-06-26T00:00:00.000ZProposed Information Collection Activity; TANF Contingency Fund Applicationhttps://www.pharmaradar360.com/article/proposed-data-collection-submitted-for-public-comment-and-recommendations-62a3870eb31c6b22Pharma Surgeen2026-06-26T00:00:00.000ZProposed Data Collection Submitted for Public Comment and Recommendationshttps://www.pharmaradar360.com/article/determination-that-prednisolone-tablet-5-milligrams-was-not-withdrawn-from-sale-5cbb9930f4b8110cPharma Surgeen2026-06-26T00:00:00.000ZDetermination That Prednisolone Tablet, 5 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectivenesshttps://www.pharmaradar360.com/article/agency-forms-undergoing-paperwork-reduction-act-review-0ce06407fb5fbc40Pharma Surgeen2026-06-26T00:00:00.000ZAgency Forms Undergoing Paperwork Reduction Act Reviewhttps://www.pharmaradar360.com/article/determination-that-rectiv-nitroglycerin-ointment-0-4-was-not-withdrawn-from-sale-78aacdef6bdfd448Pharma Surgeen2026-06-26T00:00:00.000ZDetermination That RECTIV (Nitroglycerin) Ointment, 0.4%, Was Not Withdrawn From Sale for Reasons of Safety or Effectivenesshttps://www.pharmaradar360.com/article/unaccompanied-children-program-foundational-rule-sponsor-assessment-update-to-in-79e62fa99dd15119Pharma Surgeen2026-06-26T00:00:00.000ZUnaccompanied Children Program Foundational Rule; Sponsor Assessment Update To Include Proof of Identity, Background Check, Placement, and Income Verification Standardshttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-omb-review-comment-reque-ac6642209c0f46e5Pharma Surgeen2026-06-26T00:00:00.000ZAgency Information Collection Activities: Submission for OMB Review; Comment Requesthttps://www.pharmaradar360.com/article/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-50-51dfcd447654846fPharma Surgeen2026-06-26T00:00:00.000ZList of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Periodhttps://www.pharmaradar360.com/article/drugs-for-human-use-drug-efficacy-study-implementation-estrogen-androgen-fixed-c-c14fdf1b589c4f6fPharma Surgeen2026-06-26T00:00:00.000ZDrugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661https://www.pharmaradar360.com/article/medicare-program-cy-2027-changes-to-the-end-stage-renal-disease-esrd-prospective-46be29354f50792dPharma Surgeen2026-06-26T00:00:00.000ZMedicare Program; CY 2027 Changes to the End-Stage Renal Disease (ESRD) Prospective Payment System, Acute Kidney Injury Dialysis (AKI) Payment, and ESRD Quality Incentive Programhttps://www.pharmaradar360.com/article/revocation-of-three-authorizations-of-emergency-use-of-in-vitro-diagnostic-devic-c8b1e6f1317763d8Pharma Surgeen2026-06-26T00:00:00.000ZRevocation of Three Authorizations of Emergency Use of In Vitro Diagnostic Devices for Detection and/or Diagnosis of COVID-19; Availabilityhttps://www.pharmaradar360.com/article/medical-devices-general-hospital-and-personal-use-devices-classification-of-the-deed70298e92f6c8Pharma Surgeen2026-06-26T00:00:00.000ZMedical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep Systemhttps://www.pharmaradar360.com/article/medical-devices-neurological-devices-classification-of-the-external-lower-extrem-e26723df872266e0Pharma Surgeen2026-06-26T00:00:00.000ZMedical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs Syndromehttps://www.pharmaradar360.com/article/medical-devices-general-and-plastic-surgery-devices-classification-of-the-breast-4889dc353305df41Pharma Surgeen2026-06-26T00:00:00.000ZMedical Devices; General and Plastic Surgery Devices; Classification of the Breast Implant Suction Retrieval Systemhttps://www.pharmaradar360.com/article/medical-devices-immunology-and-microbiology-devices-classification-of-the-sars-c-f3473c1857637408Pharma Surgeen2026-06-26T00:00:00.000ZMedical Devices; Immunology and Microbiology Devices; Classification of the SARS-CoV-2 Serology Testhttps://www.pharmaradar360.com/article/medical-devices-neurological-devices-classification-of-the-computerized-behavior-2bc12ac245122e6ePharma Surgeen2026-06-26T00:00:00.000ZMedical Devices; Neurological Devices; Classification of the Computerized Behavioral Therapy Device for the Treatment of Fibromyalgia Symptomshttps://www.pharmaradar360.com/article/medical-devices-clinical-chemistry-and-toxicology-devices-classification-of-the-60e5ee91ce323bfbPharma Surgeen2026-06-26T00:00:00.000ZMedical Devices; Clinical Chemistry and Toxicology Devices; Classification of the Prognostic Test for Development or Progression of Preeclampsiahttps://www.pharmaradar360.com/article/medical-devices-general-hospital-and-personal-use-devices-classification-of-the-418ff1471f13e3d9Pharma Surgeen2026-06-26T00:00:00.000ZMedical Devices; General Hospital and Personal Use Devices; Classification of the Foam or Gel Chemical Sterilant/High Level Disinfectanthttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-tim-ee7ed34151674cf3Pharma Surgeen2026-06-26T00:00:00.000ZAgency Information Collection Activities; Proposed Collection; Comment Request; Time and Extent Applications for Nonprescription Drug Productshttps://www.pharmaradar360.com/article/solicitation-for-public-comments-on-the-development-of-an-independent-accreditat-093f9298ad9301ffPharma Surgeen2026-06-26T00:00:00.000ZSolicitation for Public Comments on the Development of an Independent Accreditation System for Certified Community Behavioral Health Clinic Expansion (CCBHC-E) Grant Recipientshttps://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-1808010f787210ebPharma Surgeen2026-06-26T00:00:00.000ZCenter for Scientific Review; Notice of Closed Meetingshttps://www.pharmaradar360.com/article/cleveland-clinic-fairview-hospital-marks-major-milestone-in-expansion-with-toppi-c135cb0d87afa7c7Pharma Surgeen2026-06-26T00:00:00.000ZCleveland Clinic Fairview Hospital Marks Major Milestone in Expansion With Topping Out Ceremonyhttps://www.pharmaradar360.com/article/old-drugs-new-weapons-current-trends-in-repurposing-therapies-against-antimicrob-8cc545a5aeed9c5dPharma Surgeen2026-06-26T00:00:00.000ZOld drugs, new weapons: current trends in repurposing therapies against antimicrobial resistancehttps://www.pharmaradar360.com/article/application-of-immune-checkpoint-inhibitors-in-hepatocellular-carcinoma-a-landsc-6ea266e754ba887fPharma Surgeen2026-06-26T00:00:00.000ZApplication of immune checkpoint inhibitors in hepatocellular carcinoma: a landscape analysis of clinical trial databaseshttps://www.pharmaradar360.com/article/the-safety-and-efficacy-of-human-umbilical-cord-mesenchymal-stem-cell-for-acute-e65d2cbda0520670Pharma Surgeen2026-06-26T00:00:00.000ZThe safety and efficacy of human umbilical cord mesenchymal stem cell for acute respiratory distress syndrome: an open-label and multicenter phase 1 clinical trialhttps://www.pharmaradar360.com/article/cellular-senescence-in-periodontal-ageing-molecular-mechanisms-clinical-implicat-7fed69d660979fe9Pharma Surgeen2026-06-26T00:00:00.000ZCellular Senescence in Periodontal Ageing: Molecular Mechanisms, Clinical Implications and Emerging Therapeutic Strategieshttps://www.pharmaradar360.com/article/research-advances-and-clinical-prospects-of-cigb-300-a-novel-ck2-targeted-peptid-6e2af65ad72bf812Pharma Surgeen2026-06-26T00:00:00.000ZResearch advances and clinical prospects of CIGB-300, a novel CK2-targeted peptide inhibitor for cancer therapyhttps://www.pharmaradar360.com/article/jurisdiction-on-trial-law-morality-and-power-in-late-medieval-italy-the-domodoss-ba60d81b288c24f5Pharma Surgeen2026-06-26T00:00:00.000ZJurisdiction on Trial: Law, Morality, and Power in Late Medieval Italy. The Domodossola Case (1318–1321)https://www.pharmaradar360.com/article/bacterial-infection-and-sepsis-associated-inflammation-mechanistic-insights-and-6d9e9026bb04e2c6Pharma Surgeen2026-06-26T00:00:00.000ZBacterial infection and sepsis-associated inflammation: Mechanistic insights and emerging clinical perspectiveshttps://www.pharmaradar360.com/article/mesenchymal-stem-cells-and-their-exosomes-in-cardiac-repair-advances-and-future-dc429e11c243a8e3Pharma Surgeen2026-06-26T00:00:00.000ZMesenchymal Stem Cells and Their Exosomes in Cardiac Repair: Advances and Future Directionshttps://www.pharmaradar360.com/article/clinical-profile-and-etiological-spectrum-of-scleritis-in-a-tertiary-care-centre-2165c3f502b38ce4Pharma Surgeen2026-06-26T00:00:00.000ZClinical Profile and Etiological Spectrum of Scleritis in a Tertiary Care Centrehttps://www.pharmaradar360.com/article/management-0f-fingertip-amputations-contemporary-surgical-options-235e8dac5248f895Pharma Surgeen2026-06-26T00:00:00.000ZManagement 0f Fingertip Amputations: Contemporary Surgical Optionshttps://www.pharmaradar360.com/article/clinical-optical-bench-and-model-based-assessment-of-an-extended-depth-of-focus-fb80bdc65311e0fcPharma Surgeen2026-06-26T00:00:00.000ZClinical, optical bench, and model-based assessment of an extended depth-of-focus versus a monofocal intraocular lens: A through-focus comparative studyhttps://www.pharmaradar360.com/article/beyond-skills-reimagining-clinical-education-for-a-transformative-future-2896b8b071127ac8Pharma Surgeen2026-06-26T00:00:00.000ZBeyond skills: Reimagining clinical education for a transformative futurehttps://www.pharmaradar360.com/article/literature-based-peer-support-to-enhance-self-acceptance-among-university-studen-3800d64fae6bd80cPharma Surgeen2026-06-26T00:00:00.000ZLiterature-Based Peer Support to Enhance Self-Acceptance Among University Studentshttps://www.pharmaradar360.com/article/digital-diseases-cb1a91384ca21b43Pharma Surgeen2026-06-26T00:00:00.000ZDigital Diseaseshttps://www.pharmaradar360.com/article/the-evolution-of-nerve-sparing-radical-prostatectomy-mechanisms-of-injury-econom-d5f1f5c8878159c8Pharma Surgeen2026-06-26T00:00:00.000ZThe Evolution of Nerve-Sparing Radical Prostatectomy: Mechanisms of Injury, Economic Impact, and the Potential Value of Intraoperative Nerve Visualizationhttps://www.pharmaradar360.com/article/time-dependent-association-of-thoracic-anthropometric-parameters-with-survival-a-07810224c2bf3104Pharma Surgeen2026-06-26T00:00:00.000ZTime-Dependent Association of Thoracic Anthropometric Parameters with Survival After In-Hospital Cardiac Arrest: A Retrospective Single-Center Observational Studyhttps://www.pharmaradar360.com/article/high-intensity-interval-training-on-cardiorespiratory-fitness-cognitive-function-f652ee812b48c75bPharma Surgeen2026-06-26T00:00:00.000ZHigh-Intensity Interval Training on Cardiorespiratory Fitness, Cognitive Function, and Functional Capacity in Adults with Stroke: A Systematic Review and Meta-Analysishttps://www.pharmaradar360.com/article/prevalence-and-risk-factors-of-hypernatremic-dehydration-in-exclusively-breastfe-63ebaca6121d0010Pharma Surgeen2026-06-26T00:00:00.000ZPrevalence and Risk Factors of Hypernatremic Dehydration in Exclusively Breastfed Neonates: A Systematic Review and Meta-Analysishttps://www.pharmaradar360.com/article/from-pandemic-innovation-to-platform-diversification-a-systematic-review-of-clin-fe6a7b851ef872eePharma Surgeen2026-06-26T00:00:00.000ZFrom Pandemic Innovation to Platform Diversification: A Systematic Review of Clinical and Preclinical Development of Non–SARS-CoV-2 mRNA Vaccineshttps://www.pharmaradar360.com/article/a-conceptual-clinical-reasoning-framework-for-early-syndromic-recognition-in-den-f763499f1a985b11Pharma Surgeen2026-06-26T00:00:00.000ZA conceptual clinical reasoning framework for early syndromic recognition in dental practicehttps://www.pharmaradar360.com/article/efficacy-and-predictors-of-cognitive-stimulation-therapy-combined-with-pharmacot-6180b954119c4d81Pharma Surgeen2026-06-26T00:00:00.000ZEfficacy and predictors of cognitive stimulation therapy combined with pharmacotherapy for mild-to-moderate Alzheimer’s disease: a randomized controlled trialhttps://www.pharmaradar360.com/article/editorial-advances-in-biomarkers-and-drug-targets-harnessing-traditional-and-ai-e31089ef5d055e10Pharma Surgeen2026-06-26T00:00:00.000ZEditorial: Advances in biomarkers and drug targets: harnessing traditional and AI approaches for novel therapeutic mechanismshttps://www.pharmaradar360.com/article/a-scoping-review-of-influenza-rdrp-targeting-inhibitors-mechanisms-clinical-tran-c1a19aefb63d195cPharma Surgeen2026-06-26T00:00:00.000ZA scoping review of influenza RdRp-targeting inhibitors: mechanisms, clinical translation, and emerging challengeshttps://www.pharmaradar360.com/article/early-prediction-of-late-pregnancy-hypertriglyceridemia-in-women-with-gestationa-5f48196cadf66466Pharma Surgeen2026-06-26T00:00:00.000ZEarly prediction of late-pregnancy hypertriglyceridemia in women with gestational diabetes: development and internal validation of a clinical risk modelhttps://www.pharmaradar360.com/article/advanced-hybrid-closed-loop-therapy-in-an-older-adult-with-55-year-type-1-diabet-14be449ab937eee2Pharma Surgeen2026-06-26T00:00:00.000ZAdvanced hybrid closed-loop therapy in an older adult with 55-year type 1 diabetes: a CARE-based case reporthttps://www.pharmaradar360.com/article/mindfulness-improves-stress-and-psycho-social-morbidities-of-cancer-patients-a-c-1b07df407c18522cPharma Surgeen2026-06-26T00:00:00.000ZMindfulness improves stress and psycho-social morbidities of cancer patients: a clinical trial using community group-therapy in the Indian contexthttps://www.pharmaradar360.com/article/analyzing-the-impact-of-post-covid-19-dynamics-on-coir-production-in-theni-distr-eacad6065e62029aPharma Surgeen2026-06-26T00:00:00.000ZAnalyzing The Impact Of Post-Covid-19 Dynamics On Coir Production In Theni Districthttps://www.pharmaradar360.com/article/optimization-development-and-evaluation-of-buccal-patch-loaded-sitagliptin-using-59d297b2ca9fb101Pharma Surgeen2026-06-26T00:00:00.000ZOptimization, Development and Evaluation of Buccal patch loaded Sitagliptin using natural polymershttps://www.pharmaradar360.com/article/pharmacometric-generative-stochastic-modeling-of-patient-reported-outcome-measur-43459bbc75530a9bPharma Surgeen2026-06-26T00:00:00.000ZPharmacometric generative stochastic modeling of patient-reported outcome measureshttps://www.pharmaradar360.com/article/the-potential-of-a-selective-anxiolytic-afobazole-in-clinical-practice-2b76f2177db6cd5ePharma Surgeen2026-06-26T00:00:00.000ZThe potential of a selective anxiolytic afobazole in clinical practicehttps://www.pharmaradar360.com/article/a-clinical-case-of-anxiety-hypochondriacal-depression-with-extensive-somatized-s-ba85e11c5cc42618Pharma Surgeen2026-06-26T00:00:00.000ZA clinical case of anxiety-hypochondriacal depression with extensive somatized symptoms in the elderlyhttps://www.pharmaradar360.com/article/clinical-efficacy-of-inosine-pranobex-in-combination-therapy-of-infectious-disea-592f996496b96957Pharma Surgeen2026-06-26T00:00:00.000ZClinical efficacy of inosine pranobex in combination therapy of infectious diseaseshttps://www.pharmaradar360.com/article/the-effect-of-sebia-s-cze-ifcc-converted-results-on-carbohydrate-deficient-trans-046c76ab63c9f880Pharma Surgeen2026-06-26T00:00:00.000ZThe effect of Sebia’s CZE IFCC-converted results on carbohydrate-deficient transferrin (CDT) interpretation in driver’s license assessmentshttps://www.pharmaradar360.com/article/monostotic-chronic-nonbacterial-osteomyelitis-chronic-recurrent-multifocal-osteo-5cd09a887570ef0aPharma Surgeen2026-06-26T00:00:00.000ZMonostotic chronic nonbacterial osteomyelitis/chronic recurrent multifocal osteomyelitis of clavicle mimicking malignant bone tumor: A case report and review of literaturehttps://www.pharmaradar360.com/article/extrapulmonary-tuberculosis-presenting-with-proximal-esophageal-fistula-and-abdo-b9ebfac5f3861094Pharma Surgeen2026-06-26T00:00:00.000ZExtrapulmonary tuberculosis presenting with proximal esophageal fistula and abdominal lymphadenopathy in a young man: A case reporthttps://www.pharmaradar360.com/article/retraction-neoadjuvant-adebrelimab-plus-chemotherapy-in-untreated-locally-advanc-3b7fb1d9ae9efa66Pharma Surgeen2026-06-26T00:00:00.000ZRetraction: Neoadjuvant Adebrelimab Plus Chemotherapy in Untreated Locally Advanced Head and Neck Squamous Cell Carcinoma: Efficacy and Biomarker Insights From a Single-Arm Phase II Trialhttps://www.pharmaradar360.com/article/trends-patterns-and-demographic-dynamics-of-drug-resistance-in-i-mycobacterium-t-5c21e84efa528da6Pharma Surgeen2026-06-26T00:00:00.000ZTrends, Patterns, and Demographic Dynamics of Drug Resistance in <i>Mycobacterium tuberculosis</i> and Nontuberculous: A Multi-Year Analysis at the National Tuberculosis Reference Laboratoryhttps://www.pharmaradar360.com/article/unlocking-the-scar-ultrasound-guided-hydrodissection-for-post-surgical-radial-ne-fa4fc2ebaf16d652Pharma Surgeen2026-06-26T00:00:00.000ZUnlocking the scar: ultrasound-guided hydrodissection for post-surgical radial nerve entrapment following clinical plateauhttps://www.pharmaradar360.com/article/commentary-on-impact-of-computer-aided-detection-on-endoscopist-s-gaze-shift-dis-5396377f8419f5b7Pharma Surgeen2026-06-26T00:00:00.000ZCommentary on “Impact of Computer‐Aided Detection on Endoscopist's Gaze‐Shift Distance During Colonoscopy: A Randomized Controlled Trial”https://www.pharmaradar360.com/article/interpreting-severity-in-atopic-dermatitis-refining-severity-bands-using-clinica-46d48746bf1d195dPharma Surgeen2026-06-26T00:00:00.000ZInterpreting severity in atopic dermatitis: Refining severity bands using clinical trial datahttps://www.pharmaradar360.com/article/the-impact-of-everyday-acoustic-environments-on-chronic-pain-mechanisms-in-fibro-d5ff88d1c2dec80aPharma Surgeen2026-06-26T00:00:00.000ZThe impact of everyday acoustic environments on chronic pain mechanisms in fibromyalgia: a randomized, triple-blind, placebo-controlled 4 × 4 crossover trialhttps://www.pharmaradar360.com/article/cui-curate-a-graphrag-based-framework-for-automated-clinical-concept-curation-fo-a2776017ae620193Pharma Surgeen2026-06-26T00:00:00.000ZCUI-Curate: a GraphRAG-based framework for automated clinical concept curation for NLP applicationshttps://www.pharmaradar360.com/article/dropless-after-cataract-surgery-dacs-concepts-evidence-and-clinical-potential-cc835707e4db0c8cPharma Surgeen2026-06-26T00:00:00.000ZDropless after cataract surgery (DACS): concepts, evidence and clinical potentialhttps://www.pharmaradar360.com/article/maternal-and-congenital-syphilis-in-fiji-2019-2022-a-secondary-analysis-of-clini-b25b07826858e3bfPharma Surgeen2026-06-26T00:00:00.000ZMaternal and congenital syphilis in Fiji 2019-2022: a secondary analysis of clinical trial datahttps://www.pharmaradar360.com/article/unveiling-the-best-fit-comparative-perspective-on-animal-models-used-for-chronic-7ed6db05db5cf9f1Pharma Surgeen2026-06-26T00:00:00.000ZUnveiling the Best Fit: Comparative Perspective on Animal Models Used for Chronic Diseaseshttps://www.pharmaradar360.com/article/investigating-the-impact-of-calcium-channel-blockers-on-the-pharmacokinetics-of-b726471d3ad278e5Pharma Surgeen2026-06-26T00:00:00.000ZInvestigating the Impact of Calcium Channel Blockers on the Pharmacokinetics of Lapatinib: Possible Role of Cytochrome P450 Enzymes and P-glycoprotein Efflux Transportershttps://www.pharmaradar360.com/article/resection-of-the-mesentery-vs-kono-s-anastomosis-in-preventing-surgical-recurren-75b079fd0bf5b1f6Pharma Surgeen2026-06-26T00:00:00.000ZResection of the mesentery vs Kono-S anastomosis in preventing surgical recurrence for primary Crohn disease: the REMEASURE prospective, randomized, controlled trialhttps://www.pharmaradar360.com/article/prevention-of-acute-enteritis-by-zno-nanoparticles-green-synthesized-using-leonu-7133101af38ad05aPharma Surgeen2026-06-26T00:00:00.000ZPrevention of Acute Enteritis by ZnO Nanoparticles Green-Synthesized using Leonurus japonicus Leaf Extracthttps://www.pharmaradar360.com/article/development-of-a-clinical-decision-support-system-for-exercise-prescription-amon-13b4b6af3c0ede25Pharma Surgeen2026-06-26T00:00:00.000ZDevelopment of a clinical decision support system for exercise prescription among cancer survivors: a modified Delphi studyhttps://www.pharmaradar360.com/article/dengue-and-natural-products-unveiling-nature-s-potential-in-antiviral-drug-disco-6a80819ab90ce492Pharma Surgeen2026-06-26T00:00:00.000ZDengue and natural products: unveiling nature’s potential in antiviral drug discoveryhttps://www.pharmaradar360.com/article/long-term-analysis-of-fibrosis-in-neovascular-age-related-macular-degeneration-a-07fa3bf7193a0eebPharma Surgeen2026-06-26T00:00:00.000ZLong-term analysis of fibrosis in neovascular age-related macular degeneration: A 7-year follow-uphttps://www.pharmaradar360.com/article/clinical-utility-of-18f-fet-pet-imaging-in-pediatric-brain-tumors-a-case-series-bdd848e99490ed6fPharma Surgeen2026-06-26T00:00:00.000ZClinical utility of [18F]-FET PET Imaging in pediatric brain tumors: a case serieshttps://www.pharmaradar360.com/article/secondary-peritoneal-leiomyomatosis-after-uterine-leiomyoma-intervention-multi-i-28f89c5b52626f30Pharma Surgeen2026-06-26T00:00:00.000ZSecondary peritoneal leiomyomatosis after uterine leiomyoma intervention: multi-institutional clinical and radiologic experiencehttps://www.pharmaradar360.com/article/what-is-the-risk-of-hcc-in-hypervascular-li-rads-3-observations-without-ancillar-fa3e16eb2efc9737Pharma Surgeen2026-06-26T00:00:00.000ZWhat is the risk of HCC in hypervascular LI-RADS 3 observations without ancillary features in routine clinical practice?https://www.pharmaradar360.com/article/routine-circumferential-patellar-denervation-during-total-knee-arthroplasty-did-ce8fc36f129e9866Pharma Surgeen2026-06-26T00:00:00.000ZRoutine circumferential patellar denervation during total knee arthroplasty did not consistently eliminate neural structures at the lateral patellar border: A prospective randomised controlled trial with histological outcomeshttps://www.pharmaradar360.com/article/smile-beyond-borders-gender-academic-level-and-contextual-cross-cultural-smile-s-d3ba55912b82ae25Pharma Surgeen2026-06-26T00:00:00.000ZSmile beyond Borders: Gender, Academic Level, and Contextual Cross‐Cultural Smile Self‐Perception among Preclinical and Clinical Dental Studentshttps://www.pharmaradar360.com/article/nct07672314-bridging-the-gap-in-psychosocial-care-for-cancer-survivors-7639d83237ab5453Pharma Surgeen2026-06-26T00:00:00.000ZNCT07672314: Bridging the Gap in Psychosocial Care for Cancer Survivorshttps://www.pharmaradar360.com/article/nct07671989-period-pills-for-menstrual-regulation-a-new-reproductive-health-opti-558d989d9f6ebce3Pharma Surgeen2026-06-26T00:00:00.000ZNCT07671989: Period Pills for Menstrual Regulation: A New Reproductive Health Optionhttps://www.pharmaradar360.com/article/nct07671963-bone-substitutes-and-nipsa-in-intrabony-periodontal-defects-a-random-480dc3b1e98098b5Pharma Surgeen2026-06-26T00:00:00.000ZNCT07671963: Bone Substitutes and NIPSA in Intrabony Periodontal Defects: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/nct07671898-comparison-of-focal-cryoablation-vs-radiofrequency-cardioneuroablati-a28eab8741da5c1cPharma Surgeen2026-06-26T00:00:00.000ZNCT07671898: Comparison of Focal Cryoablation vs. Radiofrequency Cardioneuroablation for Bradyarrhythmiashttps://www.pharmaradar360.com/article/nct07671378-a-study-of-mrd-guided-zanubrutinib-plus-sonrotoclax-in-treatment-nai-f9d81370fa38e649Pharma Surgeen2026-06-26T00:00:00.000ZNCT07671378: A Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatment-Naïve, High-Risk CLL/SLL Patientshttps://www.pharmaradar360.com/article/nct07671274-comparison-of-the-efficacy-of-conventional-versus-minimally-invasive-b32a793b36f757c6Pharma Surgeen2026-06-26T00:00:00.000ZNCT07671274: Comparison of the Efficacy of Conventional Versus Minimally Invasive Non-Surgical Periodontal Therapy in Periodontitis Patientshttps://www.pharmaradar360.com/article/nct07671248-tirzepatide-in-the-treatment-of-cannabis-use-disorder-a-proof-of-con-d25a8508ccd115abPharma Surgeen2026-06-26T00:00:00.000ZNCT07671248: Tirzepatide in the Treatment of Cannabis Use Disorder: A Proof-of-Concept Studyhttps://www.pharmaradar360.com/article/nct07671092-imaging-study-of-a-trop2-binder-in-metastatic-uc-hr-and-her2-breast-9403545c79946691Pharma Surgeen2026-06-26T00:00:00.000ZNCT07671092: Imaging Study of a TROP2 Binder in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLChttps://www.pharmaradar360.com/article/nct07670741-community-blood-pressure-screening-and-cardiovascular-risk-assessmen-9946726757de06c1Pharma Surgeen2026-06-26T00:00:00.000ZNCT07670741: Community Blood Pressure Screening and Cardiovascular Risk Assessment in Croatiahttps://www.pharmaradar360.com/article/nct07670312-evaluation-of-xya02-in-patients-with-advanced-solid-tumors-440162864358cbefPharma Surgeen2026-06-26T00:00:00.000ZNCT07670312: Evaluation of XYA02 in Patients With Advanced Solid Tumorshttps://www.pharmaradar360.com/article/nct07667400-docetaxel-and-sx-682-in-recurrent-metastatic-head-and-neck-squamous-eb782075b524b62cPharma Surgeen2026-06-26T00:00:00.000ZNCT07667400: Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancerhttps://www.pharmaradar360.com/article/nct07666035-female-sexual-function-after-surgery-for-benign-perianal-diseases-1a07732da275efdfPharma Surgeen2026-06-26T00:00:00.000ZNCT07666035: Female Sexual Function After Surgery for Benign Perianal Diseaseshttps://www.pharmaradar360.com/article/nct07622472-remote-monitoring-and-optimization-of-heart-failure-therapy-c364b1a3c7218837Pharma Surgeen2026-06-26T00:00:00.000ZNCT07622472: Remote Monitoring and Optimization of Heart Failure Therapyhttps://www.pharmaradar360.com/article/nct07615010-a-clinical-trial-to-evaluate-agent-797-plus-standard-of-care-in-part-f7ef6f7e8e9a922bPharma Surgeen2026-06-26T00:00:00.000ZNCT07615010: A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failurehttps://www.pharmaradar360.com/article/nct07566481-stress-coping-and-sleep-health-study-bbb76703eb7d29f6Pharma Surgeen2026-06-26T00:00:00.000ZNCT07566481: Stress, Coping, and Sleep Health Studyhttps://www.pharmaradar360.com/article/nct07536308-a-safety-and-immunogenicity-trial-of-ocu500-chad36-vector-encoding-s-0e8a6e59eb441be3Pharma Surgeen2026-06-26T00:00:00.000ZNCT07536308: A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adultshttps://www.pharmaradar360.com/article/nct07521865-remote-technologies-in-early-stages-of-alzheimer-s-disease-9e9cf43714c17c3fPharma Surgeen2026-06-26T00:00:00.000ZNCT07521865: Remote Technologies in Early Stages of Alzheimer's Diseasehttps://www.pharmaradar360.com/article/nct07425054-cthpvdna-response-adapted-chemoradiation-retifanlimab-treatment-in-l-6eee32e27a89ea41Pharma Surgeen2026-06-26T00:00:00.000ZNCT07425054: ctHPVDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Locally-Advanced Anal Cancerhttps://www.pharmaradar360.com/article/nct07361510-a-study-to-evaluate-the-efficacy-of-pumitamig-versus-pembrolizumab-i-d12ee2f167f74af1Pharma Surgeen2026-06-26T00:00:00.000ZNCT07361510: A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)https://www.pharmaradar360.com/article/nct07255820-dual-vs-triple-lipid-lowering-therapy-in-type-2-diabetes-mellitus-pa-68ad27d9bcfb8f30Pharma Surgeen2026-06-26T00:00:00.000ZNCT07255820: Dual vs Triple Lipid-Lowering Therapy in Type 2 Diabetes Mellitus Patients With Elevated LDL Cholesterolhttps://www.pharmaradar360.com/article/nct07195734-testing-the-addition-of-chemotherapy-or-chemo-immunotherapy-to-the-u-eaef4d5ec3a3e699Pharma Surgeen2026-06-26T00:00:00.000ZNCT07195734: Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancerhttps://www.pharmaradar360.com/article/nct07140016-a-study-of-gilteritinib-in-adults-with-advanced-alk-positive-non-sma-8828378cae857731Pharma Surgeen2026-06-26T00:00:00.000ZNCT07140016: A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)https://www.pharmaradar360.com/article/nct07063745-a-study-to-compare-the-combination-of-navlimetostat-bms-986504-with-295f5525e6ec34bePharma Surgeen2026-06-26T00:00:00.000ZNCT07063745: A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletionhttps://www.pharmaradar360.com/article/nct06995677-efficacy-and-safety-of-tyra-300-in-participants-with-fgfr3-altered-l-fec8ff310e7c5ddaPharma Surgeen2026-06-26T00:00:00.000ZNCT06995677: Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancerhttps://www.pharmaradar360.com/article/nct06951698-a-study-to-evaluate-the-efficacy-and-safety-of-karxt-for-the-treatme-e4bf0996734e2db8Pharma Surgeen2026-06-26T00:00:00.000ZNCT06951698: A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorderhttps://www.pharmaradar360.com/article/nct06948097-syk-inhibition-in-mitigating-lung-allograft-rejection-similar-a-tria-28f73f1ac769add4Pharma Surgeen2026-06-26T00:00:00.000ZNCT06948097: Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fostamatinib in Lung Transplant Patients With Donor-Specific Antibodieshttps://www.pharmaradar360.com/article/nct06726954-repetitive-transcranial-magnetic-stimulation-therapy-in-spinal-cord-67f1d2894d030757Pharma Surgeen2026-06-26T00:00:00.000ZNCT06726954: Repetitive Transcranial Magnetic Stimulation Therapy in Spinal Cord Injury Related Neuropathic Painhttps://www.pharmaradar360.com/article/nct06694454-neoadjuvant-inhaled-azacytidine-with-platinum-based-chemotherapy-and-0c2ce5ad67f1e6f8Pharma Surgeen2026-06-26T00:00:00.000ZNCT06694454: Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)https://www.pharmaradar360.com/article/nct06487481-study-of-preoperative-radiation-therapy-in-participants-with-resecta-fc044139700317d0Pharma Surgeen2026-06-26T00:00:00.000ZNCT06487481: Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinomahttps://www.pharmaradar360.com/article/nct06052631-microneurographic-assessment-of-peripheral-nerves-in-healthy-volunte-19ef87b4db826563Pharma Surgeen2026-06-26T00:00:00.000ZNCT06052631: Microneurographic Assessment of Peripheral Nerves in Healthy Volunteers and Individuals With Sensory Dysfunction Caused by Inherited Mutations in the PIEZO2 Genehttps://www.pharmaradar360.com/article/nct05496335-a-study-to-evaluate-sequential-administration-of-agn-151586-and-onab-ae80887accd61dbaPharma Surgeen2026-06-26T00:00:00.000ZNCT05496335: A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult Participants for Treatment of Glabellar Lineshttps://www.pharmaradar360.com/article/nct05301816-pdn-post-market-multicenter-prospective-global-clinical-study-a380010f07c35b6aPharma Surgeen2026-06-26T00:00:00.000ZNCT05301816: PDN Post Market, Multicenter, Prospective, Global Clinical Studyhttps://www.pharmaradar360.com/article/nct05120284-trial-of-dichloroacetate-dca-in-glioblastoma-multiforme-gbm-5afeb4b902ae91c1Pharma Surgeen2026-06-26T00:00:00.000ZNCT05120284: Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM)https://www.pharmaradar360.com/article/nct05056740-combined-analysis-of-inflammatory-biomarkers-for-cns-autoimmune-dise-720f683a17ccba2fPharma Surgeen2026-06-26T00:00:00.000ZNCT05056740: Combined Analysis of Inflammatory Biomarkers for CNS Autoimmune Diseases Diagnostichttps://www.pharmaradar360.com/article/nct04423523-plasma-levels-of-danger-associated-molecular-patterns-in-young-child-45e9664660949605Pharma Surgeen2026-06-26T00:00:00.000ZNCT04423523: Plasma Levels of Danger-Associated Molecular Patterns in Young Children After Cardiac Surgery Under Cardiopulmonary Bypasshttps://www.pharmaradar360.com/article/nct04051346-dietary-oxalate-and-innate-immunity-in-kidney-stone-disease-cadcd9105b0b1f7bPharma Surgeen2026-06-26T00:00:00.000ZNCT04051346: Dietary Oxalate and Innate Immunity in Kidney Stone Diseasehttps://www.pharmaradar360.com/article/nct03691714-durvalumab-medi4736-with-cetuximab-in-previously-treated-recurrent-o-5959112661ba6d93Pharma Surgeen2026-06-26T00:00:00.000ZNCT03691714: Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinomahttps://www.pharmaradar360.com/article/nct03680846-comparison-of-hf10-therapy-combined-with-cmm-to-cmm-alone-in-the-tre-f63880fda5b4347ePharma Surgeen2026-06-26T00:00:00.000ZNCT03680846: Comparison of HF10 Therapy Combined With CMM to CMM Alone in the Treatment of Non-Surgical Refractory Back Painhttps://www.pharmaradar360.com/article/nct02231879-plerixafor-versus-g-csf-in-the-treatment-of-people-with-whim-syndrom-5b6134f76c17e7c2Pharma Surgeen2026-06-26T00:00:00.000ZNCT02231879: Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndromehttps://www.pharmaradar360.com/article/nct01274338-ipilimumab-or-high-dose-interferon-alfa-2b-in-treating-patients-with-4908044ca7683ff0Pharma Surgeen2026-06-26T00:00:00.000ZNCT01274338: Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgeryhttps://www.pharmaradar360.com/article/a-ban-won-t-stop-abortion-pill-access-telehealth-providers-say-118580ca83bf5810Pharma Surgeen2026-06-25T23:00:04.000ZA ban won't stop abortion pill access, telehealth providers sayhttps://www.pharmaradar360.com/article/fosun-pharma-plots-global-push-beyond-oncology-fueled-by-multi-asset-alzheimer-s-912ab5644687f588Pharma Surgeen2026-06-25T23:00:00.000ZFosun Pharma plots global push beyond oncology, fueled by multi-asset Alzheimer’s strategyhttps://www.pharmaradar360.com/article/bio-notebook-more-us-fda-wordplay-big-pharma-helps-entrances-biotech-m-a-offers-cfb8a7e6b64fa1d3Pharma Surgeen2026-06-25T22:10:56.000ZBIO Notebook: More US FDA Wordplay, Big Pharma Helps Entrances, Biotech M&A Offers Exitshttps://www.pharmaradar360.com/article/bio-notebook-big-pharmas-help-with-entrances-biotech-m-a-offers-exits-e337d796d0769c4cPharma Surgeen2026-06-25T20:48:34.000ZBIO Notebook: Big Pharmas Help With Entrances; Biotech M&A Offers Exitshttps://www.pharmaradar360.com/article/scientists-measure-hidden-quantum-forces-that-could-power-a-new-generation-of-ph-064530258cc8de68Pharma Surgeen2026-06-25T20:20:10.000ZScientists measure hidden quantum forces that could power a new generation of pharmaceutical drugshttps://www.pharmaradar360.com/article/orforglipron-news-foundayo-fda-approved-for-weight-loss-4438c6075538dfbaPharma Surgeen2026-06-25T19:51:13.000ZOrforglipron News: Foundayo FDA Approved for Weight losshttps://www.pharmaradar360.com/article/14-new-weight-loss-drugs-8f97f67645d6c678Pharma Surgeen2026-06-25T19:21:05.000Z14 New Weight Loss Drugshttps://www.pharmaradar360.com/article/fda-clears-trodelvy-for-first-line-metastatic-triple-negative-breast-cancer-phar-8d7096302d877668Pharma Surgeen2026-06-25T19:03:16.000ZFDA Clears Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer | PharmExechttps://www.pharmaradar360.com/article/bio-2026-fda-leadership-confront-workforce-losses-china-competition-in-drug-deve-e6715ab3f4d88357Pharma Surgeen2026-06-25T19:00:08.000ZBIO 2026: FDA Leadership Confront Workforce Losses, China Competition in Drug Developmenthttps://www.pharmaradar360.com/article/patient-perceptions-on-the-use-of-ai-in-creating-clinical-research-documents-sur-ef3ac9fbae58b2dePharma Surgeen2026-06-25T18:46:56.000ZPatient Perceptions on the Use of AI in Creating Clinical Research Documents: Survey Studyhttps://www.pharmaradar360.com/article/nipah-virus-disease-india-4ba4a82cc627e48dPharma Surgeen2026-06-25T18:00:00.000ZNipah virus disease - Indiahttps://www.pharmaradar360.com/article/atea-completes-enrollment-in-phase-3-hepatitis-c-trial-988b6fba4c56b860Pharma Surgeen2026-06-25T17:31:50.000ZAtea completes enrollment in phase 3 hepatitis C trialhttps://www.pharmaradar360.com/article/pinnacle-biologics-receives-untitled-letter-from-fda-for-photofrin-a5b982ab392cb95ePharma Surgeen2026-06-25T17:02:20.000ZPinnacle Biologics receives Untitled Letter from FDA for Photofrinhttps://www.pharmaradar360.com/article/fda-says-infant-formula-is-safe-critics-say-agency-left-out-key-information-c8255243ce39189fPharma Surgeen2026-06-25T16:35:04.000ZFDA says infant formula is safe. Critics say agency left out key information.https://www.pharmaradar360.com/article/notifiable-diseases-causative-agents-reports-for-2026-32900b46450305d4Pharma Surgeen2026-06-25T16:23:37.000ZNotifiable diseases: causative agents reports for 2026https://www.pharmaradar360.com/article/drug-to-prevent-organ-rejection-after-kidney-transplant-tops-standard-treatment-4add60b421db13b6Pharma Surgeen2026-06-25T16:11:35.000ZDrug to prevent organ rejection after kidney transplant tops standard treatment in trialhttps://www.pharmaradar360.com/article/fda-will-reportedly-conclude-abortion-pill-safety-review-by-september-343203b30dba9d6dPharma Surgeen2026-06-25T16:06:00.000ZFDA Will Reportedly Conclude Abortion Pill Safety Review by Septemberhttps://www.pharmaradar360.com/article/senate-unanimously-passes-boscola-backed-legislation-to-modernize-pharmaceutical-66ce988cc92e19cePharma Surgeen2026-06-25T15:41:09.000ZSenate Unanimously Passes Boscola-Backed Legislation to Modernize Pharmaceutical Licensinghttps://www.pharmaradar360.com/article/therapeutics-stocks-q1-teardown-biomarin-pharmaceutical-nasdaq-bmrn-vs-the-rest-56344bfd686cf92dPharma Surgeen2026-06-25T15:37:50.000ZTherapeutics Stocks Q1 Teardown: BioMarin Pharmaceutical (NASDAQ:BMRN) Vs The Resthttps://www.pharmaradar360.com/article/tianjin-development-says-lisheng-pharmaceutical-subscribes-to-investment-product-5908f523f0d969d3Pharma Surgeen2026-06-25T15:33:51.000ZTianjin Development Says Lisheng Pharmaceutical Subscribes To Investment Products Totaling RMB180 Millionhttps://www.pharmaradar360.com/article/biotech-etf-index-surges-10-after-rebalance-1edcbf3595d1bd45Pharma Surgeen2026-06-25T15:32:51.000ZBiotech ETF Index Surges 10% After Rebalancehttps://www.pharmaradar360.com/article/krystal-biotech-stock-hits-all-time-high-at-357-65-usd-4abb039116198537Pharma Surgeen2026-06-25T15:31:18.000ZKrystal Biotech stock hits all-time high at 357.65 USDhttps://www.pharmaradar360.com/article/2546-a-cluster-randomised-controlled-trial-of-air-filtration-to-prevent-symptoma-5984674e16dbc3d5Pharma Surgeen2026-06-25T15:19:35.000Z2546: A cluster randomised controlled trial of Air Filtration to prevent symptomatic winter Respiratory Infections (including COVID-19) in care homes (AFRI-c)https://www.pharmaradar360.com/article/scoop-members-of-congress-told-abortion-pill-safety-review-possible-by-september-4e04bb31595eb57fPharma Surgeen2026-06-25T15:11:08.000ZSCOOP: Members of Congress Told Abortion Pill Safety Review Possible by Septemberhttps://www.pharmaradar360.com/article/3-fragen-an-unser-neues-boardmitglied-michele-ravara-general-manager-bei-abbvie-df008236250ce191Pharma Surgeen2026-06-25T15:10:21.000Z3 Fragen an unser neues Boardmitglied: Michele Ravara, General Manager bei AbbVie Switzerlandhttps://www.pharmaradar360.com/article/geodis-tests-sustainable-paper-thermal-covers-for-pharmaceutical-airfreight-3801ee1b6af6c9bdPharma Surgeen2026-06-25T15:09:54.000ZGEODIS tests sustainable paper thermal covers for pharmaceutical airfreighthttps://www.pharmaradar360.com/article/dhsc-workforce-management-information-may-2026-b766133bf277f757Pharma Surgeen2026-06-25T15:00:08.000ZDHSC: workforce management information May 2026https://www.pharmaradar360.com/article/dhsc-senior-officials-business-expenses-hospitality-and-meetings-january-to-marc-2fa50abc78b19ba4Pharma Surgeen2026-06-25T15:00:08.000ZDHSC: senior officials’ business expenses, hospitality and meetings, January to March 2026https://www.pharmaradar360.com/article/dhsc-ministerial-travel-and-meetings-january-to-march-2026-39ee0c30f2ed7e92Pharma Surgeen2026-06-25T15:00:08.000ZDHSC: ministerial travel and meetings, January to March 2026https://www.pharmaradar360.com/article/dhsc-ministerial-gifts-hospitality-overseas-travel-and-meetings-2332d5d2f3822f2ePharma Surgeen2026-06-25T15:00:08.000ZDHSC: ministerial gifts, hospitality, overseas travel and meetingshttps://www.pharmaradar360.com/article/dhsc-workforce-management-information-62f452371af74327Pharma Surgeen2026-06-25T15:00:08.000ZDHSC: workforce management informationhttps://www.pharmaradar360.com/article/dhsc-senior-officials-business-expenses-hospitality-and-meetings-a328912eb87631b3Pharma Surgeen2026-06-25T15:00:08.000ZDHSC: senior officials’ business expenses, hospitality and meetingshttps://www.pharmaradar360.com/article/dhsc-special-advisers-gifts-hospitality-and-meetings-52d34624ad3609c5Pharma Surgeen2026-06-25T15:00:05.000ZDHSC: special advisers' gifts, hospitality and meetingshttps://www.pharmaradar360.com/article/dhsc-special-advisers-gifts-hospitality-and-meetings-january-to-march-2026-f054ee78b3c87d08Pharma Surgeen2026-06-25T15:00:04.000ZDHSC: special advisers' gifts, hospitality and meetings, January to March 2026